Prenatal Genomics —
Training activity: 3

Details

Analyse and interpret the results of QFPCR used for prenatal cases referred due to an increased screening risk, select appropriate reflex tests and prepare interpretive reports

Type

Developmental training activity (DTA)

Evidence requirements

Evidence the activity has been undertaken by the trainee​.

Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.

An action plan to implement learning and/or to address skills or knowledge gaps identified.

Reflective practice guidance

The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.

Before action

What are the intended outcomes of the training activity?

• Have you reviewed the learning outcomes to ensure you are prepared to accurately analyse and interpret QFPCR results and select appropriate reflex tests for patients referred due to an increased screening risk?
• What essential knowledge have you identified as necessary regarding the national screening programme for aneuploidy and the National Foetal Anomaly Screening Programme before you begin interpreting results?
• Have you considered how your report will address chromosomal rearrangements, including the implications for recurrence risk and recommendations for patient management?

What do you anticipate you will learn from the experience?

• What specific insights do you hope to gain regarding the limitations of QFPCR, such as the identification and impact of mosaicism, maternal cell contamination (MCC), or allele drop-out?
• How do you expect this activity to improve your proficiency in applying guidelines for identifying common aneuploidies and recognising when results fall outside the scope of rapid testing?
• In what ways do you anticipate developing your skills in reflex testing decisions, such as determining when a finding necessitates follow-up via microarray analysis or karyotyping?
• How will this experience enhance your ability to translate quantitative data into a clear interpretive report that adheres to professional standards for high-risk cases?

What actions will you take in preparation for the experience?

• Have you discussed the activity with your Training Officer to gain clarity on the expected standards for QFPCR peak interpretation, reflex testing triggers, and reporting?
• Which specific resources have you reviewed, such as QFPCR analysis protocols, criteria for reflex tests, or standard reporting templates for prenatal results?
• How have you planned to handle potential challenges, such as encountering atypical aneuploidies or unusual peak ratios that deviate from typical trisomy patterns?
• How do you feel about embarking on this activity, considering the sensitive nature of prenatal testing following an increased screening risk?
• What actions have you taken to ensure your interpretation will remain within your scope of practice and align with established laboratory protocols?

In action

What are you doing?

• How are you currently approaching the analysis of the QFPCR results, and why have you chosen this specific sequence of steps for interpreting peaks and allele ratios?
• What specific features of the data are you focusing on right now, such as unusual peak heights or ratios, and how are you determining if they indicate a common aneuploidy?
• What decisions are you making as the activity progresses regarding the classification of variants and the identification of potentially significant findings?
• What aspects of your practice feel intuitive in this moment, and which—such as interpreting complex peak patterns—require more conscious effort and reference to guidelines?

How are you progressing with the activity?

• How effectively are you identifying and characterizing genomic abnormalities, such as trisomies or structural rearrangements, that could explain the patient’s increased screening risk?
• What challenges are you encountering in this moment, such as ambiguous results, potential maternal cell contamination (MCC), or allele drop-out?
• How are you connecting these results to your existing knowledge of the maternity clinical care pathway and the principles of screening versus diagnosis?
• What are you learning from the data as it unfolds, particularly if unexpected patterns emerge that require further investigation beyond the initial QFPCR scope?

How are you adapting to the situation?

• What alternative analysis or interpretation strategies are you considering, such as reviewing raw alignment data or checking quality control metrics, if your initial assessment is unclear?
• How are you deciding which specific reflex tests, such as microarray analysis or karyotyping, are necessary to clarify an atypical result or structural rearrangement?
• What immediate support or guidance have you identified as necessary from a senior colleague or clinical scientist to justify your reflex testing decisions?
• How are you ensuring that your interpretation and draft report remain within your scope of practice while addressing the clinical question and implications for the family?
• In what ways are you adjusting your reporting style to ensure that recurrence risks and management recommendations are clear and adhere to professional standards?

On action

What did you notice?

• How would you summarise the key points of the QFPCR results you analysed, specifically regarding the patterns indicative of common aneuploidies (Trisomies 13, 18, and 21) or sex chromosome abnormalities?
• What specific actions or interactions felt most important during the interpretation process, such as performing dosage calculations or identifying unusual peak ratios that suggested potential mosaicism?
• Which ‘reflect-in-action’ moments did you notice where you had to adapt as the data unfolded, such as immediately deciding to recommend a reflex microarray or karyotype based on an ambiguous result?
• What were your feelings while interpreting these high-stakes results, knowing they follow a clinical referral for increased screening risk?

What did you learn from the activity?

• What specific skills or knowledge did you develop regarding the technical limitations of QFPCR, such as the impact of maternal cell contamination (MCC), allele drop-out, or polysomy on data integrity?
• How did you improve your ability to interpret chromosomal rearrangements and accurately communicate the implications for recurrence risk within a clinical report?
• In what ways did your real-time decisions—such as checking quality control metrics or peak heights—influence the final interpretation and the recommendations you made for patient management?
• How does this experience relate to the requirements for your future post-programme practice as a Clinical Scientist responsible for delivering timely and accurate prenatal diagnostic findings?

What will you take from the experience moving forward?

• What areas for continued development have been identified, such as a need to gain further proficiency in recognizing atypical aneuploidies or complex reflex testing criteria?
• How will you apply the learning from this activity to your routine practice, such as systematically checking QFPCR data against specific quality control metrics before proceeding to interpretation?
• What specific ‘next steps’ will you take to consolidate your learning, such as reviewing standard reporting templates or national guidelines for screen-positive results?
• What support or resources have you identified as necessary for your ongoing development, such as access to expert mentorship for complex QFPCR interpretation or further training on reflex testing strategies?

Beyond action

Have you revisited the experiences?

• Have you evaluated and re-evaluated your initial interpretations of QFPCR peaks and allele ratios to see if your understanding of aneuploidy patterns has deepened since completing this activity?
• In what ways have you reviewed your reflections across multiple training activities in the module to identify consistent learning points regarding quantitative data analysis and reflex testing strategies?
• Have you engaged in professional storytelling with peers or senior colleagues about challenging QFPCR cases, and how has their feedback on your reflex test selections (e.g., recommending a microarray) transformed your perspective?
• Have you compared the analytical practices used for QFPCR with those used for other technologies, such as microarray analysis, to see which behaviours—like identifying anomalies in quantitative data—you have successfully assimilated into your routine practice?

How have these experiences impacted upon your current practice?

• How has your ability to recognise technical limitations, such as maternal cell contamination (MCC), mosaicism, or allele drop-out, evolved and influenced the way you now screen data for quality?
• How has the accumulated learning from interpreting increased screening risk cases supported your preparation for Case-Based Discussions or clinical reports involving recurrence risk assessment?
• In what ways has your participation in multidisciplinary team (MDT) meetings provided new insights that you now apply when formulating management recommendations in your interpretive reports?
• How have you applied the skills developed here—such as quantitative analysis and clear reporting—to subsequent prenatal cases, particularly those involving complex chromosomal rearrangements?
• Can you identify specific instances where your foundational knowledge of the maternity clinical care pathway has influenced your current prioritisation of rapid testing over slower, comprehensive methods when time is critical?

How might these experiences contribute towards your future practice?

• What transferable skills in diagnostic planning and technical troubleshooting have you identified as essential for your future role as a Clinical Scientist in a prenatal setting?
• What clear actions for continued development have you defined to ensure your practice remains aligned with the National Foetal Anomaly Screening Programme and evolving best practice guidelines?
• How will your understanding of service urgency and the logistical challenges of prenatal diagnosis help you contribute to future service improvements or innovations, such as implementing new non-invasive testing applications?
• How has your appreciation for the ethical and legal dimensions of prenatal findings shaped the sensitive approach you will take when reporting results that have significant implications for a pregnancy or family?
• What strategies will you employ to stay proficient in variant classification and the use of bioinformatic tools as the genomic landscape of prenatal testing continues to advance?

Relevant learning outcomes

#	Outcome
# 1	Outcome Apply appropriate testing strategies to patients referred for increased screening risk.
# 4	Outcome Interpret chromosomal rearrangements, including implications for recurrence risk and future testing.
# 6	Outcome Interpret and report prenatal genomic findings, including appropriate recommendations for patient management.